These data indicate that SCARB2 plays critical role in maintaining the initiation and progression of HCC and targeting SCARB2-MYC interaction may serve as a therapeutic strategy for HCC by reducing the proliferation of HCC cells and inhibiting the stem cell-like characteristics of HCC cells and encourage immediate clinical translation of PMB-based therapeutics for HCC treatment (Fig. 7j). This evidence concerns the gene SCARB2 and hepatocellular carcinoma.